Rheumatology 1999; 38: 841-847
© 1999 British Society for Rheumatology
Relationship between soluble markers of immune activation and bone turnover in post-menopausal women with rheumatoid arthritis
Department of Internal Medicine IV, Friedrich-Schiller University of Jena, Germany
Correspondence to:
P. Oelzner, Department of Internal Medicine IV, Friedrich-Schiller University of Jena, Erlanger Allee 101, 07740 Jena, Germany.
Objective. Regarding interactions between pro-inflammatory cytokines and bone metabolism in rheumatoid arthritis (RA), we investigated the relationship between the serum levels of interleukin (IL)-1ß, IL-6, soluble interleukin-2 receptor (sIL-2r), C-reactive protein (CRP), the vitamin D metabolites 25-hydroxyvitamin D3 (25OHD3 ) and 1,25-dihydroxyvitamin D3 [1,25(OH)2D3 ], intact parathyroid hormone (iPTH) as well as serum and urinary parameters of bone turnover in 74 post-menopausal women with RA.
Results. SIL-2r correlated negatively with 1,25(OH)2D3 (P<0.01), whereas IL-6 showed a positive correlation with urinary excretion of deoxypyridinolinecollagen cross-links (P<0.01). 1,25(OH)2D3 (P<0.01) and iPTH (P<0.01) were negatively related to CRP, whereas the urinary excretion of pyridinoline (P<0.01) and deoxypyridinoline (P<0.01)collagen cross-links showed a positive correlation with CRP. 1,25(OH)2D3 (P<0.01) and iPTH (P<0.05) were positively related to bone alkaline phosphatase as a marker of osteoblast function.
Conclusion. Our data indicate that IL-6 is a critical determinant of increased bone resorption in post-menopausal RA women with high disease activity and that serum levels of 1,25(OH)2D3 are inversely related to T-cell activation.
KEY WORDS: Rheumatoid arthritis, Osteoporosis, Pro-inflammatory cytokines, Vitamin D, PTH.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
G. Saviola, L. Abdi. Ali, S. Shams. Eddin, A. Coppini, F. Cavalieri, L. Campostrini, S. Sacco, M. Bucci, G. Cirino, and M. Rossini Compared clinical efficacy and bone metabolic effects of low-dose deflazacort and methyl prednisolone in male inflammatory arthropathies: a 12-month open randomized pilot study Rheumatology, June 1, 2007; 46(6): 994 - 998. [Abstract] [Full Text] [PDF] |
||||
